A Registered Cohort Study of Inflammatory Demyelination Disease

To Study the Pathophysiological Features of Multiple Sclerosis

NCT04242056 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Immunisation Status and Safety of Vaccines in Italian MS Patients

NCT04300868 ·Status: UNKNOWN

Smoldering Inflammation in MS

NCT06591429 ·Status: RECRUITING

An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

NCT01838668 ·Status: COMPLETED ·Phase: PHASE3

Assessment of Patients With Multiple Sclerosis (MS)

NCT00001156 ·Status: COMPLETED

Investigating the Effect of Ocrelizumab in African Americans and Caucasians With Relapsing Multiple Sclerosis

NCT04458688 ·Status: RECRUITING

Demyelination and Remyelination in Multiple Sclerosis (MS) Detected by Brain Amyloid PET-CT

NCT05783934 ·Status: COMPLETED ·Phase: NA

Effect of Fingolimod on the Cardiac Autonomic Regulation in Patients With Multiple Sclerosis

NCT01704183 ·Status: COMPLETED

Motor Evoked Potentials as a Biomarker in Alemtuzumab Treated Multiple Sclerosis Patients

NCT02623946 ·Status: COMPLETED

Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis

NCT04380220 ·Status: UNKNOWN

Remyelination in Multiple Sclerosis: a PET-MR Longitudinal Study Investigating Individual Profiles of Myelin Repair and the Contribution of Neuroinflammation

NCT05147532 ·Status: UNKNOWN ·Phase: NA

Investigating the Utility of Demyelination Tracer [18F]3F4AP in Controls and Multiple Sclerosis Subjects

NCT04699747 ·Status: RECRUITING ·Phase: PHASE1

Patient Research Cohort: Rapidly Evolving Multiple Sclerosis

NCT01044576 ·Status: COMPLETED

MS-NEUROPLAST: Neuroplasticity of Cortical Areas Induced by Cognitive Training in Patients with Multiple Sclerosis

NCT04806568 ·Status: RECRUITING ·Phase: NA

Immunologic Biomarker Profile of Cerebrospinal Fluid

NCT04202055 ·Status: COMPLETED

Regulation of Lipid Metabolism in Autoimmune Disease: Multiple Sclerosis

NCT04053374 ·Status: UNKNOWN

Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients

NCT01767493 ·Status: COMPLETED ·Phase: PHASE4

Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis

NCT01395316 ·Status: COMPLETED ·Phase: PHASE4

Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis

NCT05134441 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by Magnetic Resonance Imaging (MRI)(0812-003)(COMPLETED)

NCT00239655 ·Status: TERMINATED ·Phase: PHASE2

Study of Neuroinflammation in Multiple Sclerosis by PET-MRI Imaging Using the Radiotracer ([18F]-DPA-714) : a Multicentre Cohort Study (INFLANET)

NCT06280742 ·Status: RECRUITING ·Phase: NA

Neurocognitive Changes in Patients With Remitting Relapsing Multiple Sclerosis Treated With Natalizumab

NCT01250678 ·Status: UNKNOWN

Effects of Ofatumumab Treatment on Immune Cells and Meningeal Lymphatic Drainage in Patients With Demyelinating Diseases

NCT05414487 ·Status: UNKNOWN

Central and Peripheral Nervous System Changes as Markers of Disease Progression in Multiple Sclerosis

NCT03401307 ·Status: COMPLETED

The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort

NCT01723709 ·Status: COMPLETED